SG10201810016XA - Methods of treating depression using nmda modulators - Google Patents

Methods of treating depression using nmda modulators

Info

Publication number
SG10201810016XA
SG10201810016XA SG10201810016XA SG10201810016XA SG10201810016XA SG 10201810016X A SG10201810016X A SG 10201810016XA SG 10201810016X A SG10201810016X A SG 10201810016XA SG 10201810016X A SG10201810016X A SG 10201810016XA SG 10201810016X A SG10201810016X A SG 10201810016XA
Authority
SG
Singapore
Prior art keywords
methods
treating depression
nmda modulators
depression
nmda
Prior art date
Application number
SG10201810016XA
Inventor
Ron Burch
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of SG10201810016XA publication Critical patent/SG10201810016XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

METHODS OF TREATING DEPRESSION USING NMDA MODULATORS This disclosure provides methods and regimens for treating depression (e.g., treatment- resistant depression) in a patient (e.g., a patient in need of such treatment). No suitable figure
SG10201810016XA 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators SG10201810016XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462037374P 2014-08-14 2014-08-14

Publications (1)

Publication Number Publication Date
SG10201810016XA true SG10201810016XA (en) 2018-12-28

Family

ID=55304631

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201701134XA SG11201701134XA (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators
SG10201810016XA SG10201810016XA (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201701134XA SG11201701134XA (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators

Country Status (18)

Country Link
US (1) US20170296616A1 (en)
EP (1) EP3180015A4 (en)
JP (2) JP2017524721A (en)
KR (1) KR20170040351A (en)
CN (1) CN106659763A (en)
AU (2) AU2015301650A1 (en)
BR (1) BR112017002930A2 (en)
CA (1) CA2957937A1 (en)
CL (1) CL2017000378A1 (en)
CO (1) CO2017002356A2 (en)
IL (1) IL250557A0 (en)
MX (1) MX2017002052A (en)
PH (1) PH12017500275A1 (en)
RU (1) RU2017107033A (en)
SG (2) SG11201701134XA (en)
UA (1) UA123623C2 (en)
WO (1) WO2016025721A1 (en)
ZA (1) ZA201701526B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018007681A2 (en) * 2015-10-16 2018-11-06 Univ Northwestern pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia, bipolar disorder, cognitive impairment and major depressive disorder
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
US20190351006A1 (en) * 2017-11-10 2019-11-21 Naurex Inc. Methods of administration of nmda receptor agonists
CN111670041A (en) * 2017-12-05 2020-09-15 诺雷克斯股份有限公司 Combination of NMDA receptor modulators (lapatin) for use in combination therapy (sleep disorders or central nervous system disorders)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
EP2813236A1 (en) * 2009-10-05 2014-12-17 Northwestern University GLYX for use in the treatment of depression or anxiety
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans

Also Published As

Publication number Publication date
CA2957937A1 (en) 2016-02-18
MX2017002052A (en) 2018-08-15
US20170296616A1 (en) 2017-10-19
IL250557A0 (en) 2017-03-30
PH12017500275A1 (en) 2017-07-03
KR20170040351A (en) 2017-04-12
UA123623C2 (en) 2021-05-05
EP3180015A4 (en) 2018-02-14
RU2017107033A (en) 2018-09-14
BR112017002930A2 (en) 2017-12-05
CL2017000378A1 (en) 2017-11-03
SG11201701134XA (en) 2017-03-30
JP2020128391A (en) 2020-08-27
WO2016025721A1 (en) 2016-02-18
RU2017107033A3 (en) 2019-02-12
EP3180015A1 (en) 2017-06-21
CO2017002356A2 (en) 2017-06-09
AU2020203165A1 (en) 2020-06-04
CN106659763A (en) 2017-05-10
AU2015301650A1 (en) 2017-03-23
ZA201701526B (en) 2018-05-30
JP2017524721A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
MX2022014331A (en) Methods and compositions for treatment of epileptic disorders.
NZ731467A (en) Anti-tim3 antibodies and methods of use
EP3443013A4 (en) Methods of using pd-l1 expression in treatment decisions for cancer therapy
MX2017011834A (en) Peptidomimetic macrocycles and uses thereof.
HK1219218A1 (en) Method for providing attachments used for orthodontic treatment and attachments
IL274855A (en) Apparatus, systems and methods for dental treatments
GB2541571A (en) Pharmaceutical compositions
IL260684B (en) Treatment for modulating gut microbiota
NZ630757A (en) Self-optimising respiratory therapy system
SG10201900574SA (en) Virtual currency conversion device, method and computer program
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
PH12017500275A1 (en) Methods of treating depression using nmda modulators
MX2017003797A (en) Peptidomimetic macrocycles and uses thereof.
MX2015011606A (en) Methods of treating cancer and preventing cancer drug resistance.
MX2017002489A (en) Human therapeutic agents.
EP3122296A4 (en) Ophthalmic treatment solution delivery devices and delivery augmentation methods
MX2017000306A (en) Methods for treating hypotension.
IL271728A (en) Agents, uses and methods for treatment
PH12017500602A1 (en) Methods for treating ocular conditions
MX2016009537A (en) Method for treating laundry.
JO3541B1 (en) Medical treatments based on anamorelin
EP3166329A4 (en) White noise generating headset for stress relaxation and concentration improvement, and white noise generating method using same
MX2016015280A (en) Anti-brdu antibodies and methods of use.
MX2020005557A (en) Fxr agonists for the treatment of liver diseases.
ZA201703222B (en) Magnetic field therapy apparatus, and method for generating a magnetic field